Intensity Therapeutics, Inc.
Intensity Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative, immune-based cancer therapies. Their mission is to help patients live longer, higher quality lives by discovering and commercializing first-in-class cancer drugs that target tumors with minimal side effects and activate the patient's immune system. Their lead product, INT230-6, is in human clinical studies for refractory solid tumors, utilizing their proprietary DfuseRx℠ technology platform to create formulations that rapidly disperse throughout tumors and diffuse into cancer cells, inducing systemic immune responses and tumor regression.
Industries
Nr. of Employees
small (1-50)
Intensity Therapeutics, Inc.
1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779
Patents
Products
INT230-6
An investigational intratumoral multi-component product consisting of two cytotoxic agents co-formulated with a penetration-enhancer designed to disperse throughout solid tumors, induce tumor necrosis, and elicit systemic immune responses.
INT230-6
An investigational intratumoral multi-component product consisting of two cytotoxic agents co-formulated with a penetration-enhancer designed to disperse throughout solid tumors, induce tumor necrosis, and elicit systemic immune responses.
Services
Discovery service using a dispersion and penetration-enhancer screening platform to create tumor-diffusing formulations matched to tumor types.
Design and conduct of intratumoral clinical studies including dose escalation, expansion cohorts, combination cohorts, and randomized Phase 2/3 trials with standard oncology endpoints.
Partnerships to evaluate combination regimens and mechanistic studies with external pharmaceutical companies and government research institutes.
Discovery service using a dispersion and penetration-enhancer screening platform to create tumor-diffusing formulations matched to tumor types.
Design and conduct of intratumoral clinical studies including dose escalation, expansion cohorts, combination cohorts, and randomized Phase 2/3 trials with standard oncology endpoints.
Partnerships to evaluate combination regimens and mechanistic studies with external pharmaceutical companies and government research institutes.
Expertise Areas
- Intratumoral therapeutic development
- Clinical trial design and execution (Phase 1–3)
- Immuno-oncology and immune monitoring
- Formulation development for tissue dispersion and cell penetration
Key Technologies
- Intratumoral drug delivery
- Cell-penetration enhancers
- Co-formulation of cytotoxic agents
- Preclinical in vivo tumor models
News & Updates
On December 28, the team from Intensity Therapeutics visited the Nasdaq MarketSite in New York’s Times Square. Lewis H. Bender, Founder, President, and CEO, rang the closing bell.
The company announced its financial results and corporate updates for the first quarter of 2025.
Lewis H. Bender, CEO of Intensity Therapeutics, was recognized as one of PharmaVoices' 100 Most Inspiring People for 2019, highlighting his leadership in the biotech industry.
On December 28, the team from Intensity Therapeutics visited the Nasdaq MarketSite in New York’s Times Square. Lewis H. Bender, Founder, President, and CEO, rang the closing bell.
The company announced its financial results and corporate updates for the first quarter of 2025.
Lewis H. Bender, CEO of Intensity Therapeutics, was recognized as one of PharmaVoices' 100 Most Inspiring People for 2019, highlighting his leadership in the biotech industry.